Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pretreatment absolute monocyte counts are associated with biological disease-modifying anti-rheumatic drug non-response in patients with rheumatoid arthritis.

Scandinavian journal of rheumatology·2025
Same author

The Effect of COVID-19 on Medication Adherence in a Rheumatoid Arthritis (BRAGGSS) and Psoriatic Arthritis (OUTPASS) UK Cohort.

The Journal of rheumatology·2023
Same author

Investigating CD11c expression as a potential genomic biomarker of response to TNF inhibitor biologics in whole blood rheumatoid arthritis samples.

Arthritis research & therapy·2015
Same author

Genome-wide association meta-analyses to identify common genetic variants associated with hallux valgus in Caucasian and African Americans.

Journal of medical genetics·2015
Same author

High-performance liquid chromatography-mass spectrometry of porphyrins by using an atmospheric pressure interface.

Journal of the American Society for Mass Spectrometry·2013
Same author

Identification of BACH2 and RAD51B as rheumatoid arthritis susceptibility loci in a meta-analysis of genome-wide data.

Arthritis and rheumatism·2013
Same journal

Single-cell profiling of the immune landscape at the maternal-fetal interface in unexplained recurrent miscarriage.

Cytokine·2026
Same journal

EGFR as a context-dependent modulator of endothelial inflammation: A systematic review.

Cytokine·2026
Same journal

Harnessing the Power of IL-12: Revolutionizing Cancer Therapy with Combinatorial Strategies.

Cytokine·2026
Same journal

Corrigendum to "CCL17 and CCL19 are markers of disease progression in alveolar echinococcosis" [Cytokine 181 (2024) 156669].

Cytokine·2026
Same journal

Efficacy and safety of IgG-pathway inhibitors in adult immune thrombocytopenia: A systematic review and meta-analysis with subgroup analyses of FcRn and SYK inhibitors.

Cytokine·2026
Same journal

Innovative immune checkpoint modulators: monoclonal antibodies, small molecules, non-coding RNAs, and nanoparticles in cancer immunotherapy.

Cytokine·2026
See all related articles

Related Experiment Video

Updated: Jul 3, 2026

Multiplex Cytokine Profiling of Stimulated Mouse Splenocytes Using a Cytometric Bead-based Immunoassay Platform
11:00

Multiplex Cytokine Profiling of Stimulated Mouse Splenocytes Using a Cytometric Bead-based Immunoassay Platform

Published on: November 9, 2017

Cytokine pharmacogenetics.

J R Maxwell1, A G Wilson

  • 1Academic Rheumatology Group, Royal Hallamshire Hospital, Sheffield, UK. J@mesmaxwell.fsnet.co.uk

Cytokine
|March 15, 2006
PubMed
Summary
This summary is machine-generated.

Genetic variation influences immune function and drug responses. Cytokine pharmacogenetics can personalize therapies for better outcomes and cost-effectiveness.

More Related Videos

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
06:37

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Published on: September 15, 2023

Microfluidic Approach to Resolve Simultaneous and Sequential Cytokine Secretion of Individual Polyfunctional Cells
09:43

Microfluidic Approach to Resolve Simultaneous and Sequential Cytokine Secretion of Individual Polyfunctional Cells

Published on: March 8, 2024

Related Experiment Videos

Last Updated: Jul 3, 2026

Multiplex Cytokine Profiling of Stimulated Mouse Splenocytes Using a Cytometric Bead-based Immunoassay Platform
11:00

Multiplex Cytokine Profiling of Stimulated Mouse Splenocytes Using a Cytometric Bead-based Immunoassay Platform

Published on: November 9, 2017

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
06:37

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Published on: September 15, 2023

Microfluidic Approach to Resolve Simultaneous and Sequential Cytokine Secretion of Individual Polyfunctional Cells
09:43

Microfluidic Approach to Resolve Simultaneous and Sequential Cytokine Secretion of Individual Polyfunctional Cells

Published on: March 8, 2024

Area of Science:

  • Pharmacogenetics
  • Immunology
  • Drug Development

Background:

  • Genetic variations impact immune system function.
  • Individual genetic differences affect drug interactions with cellular pathways.
  • Cytokine-based therapies are increasingly used in clinical practice.

Purpose of the Study:

  • To review the clinical implications of cytokine pharmacogenetics.
  • To explore targeting cytokine therapies to individuals with favorable genetic profiles.
  • To assess the pharmacoeconomic and therapeutic benefits of personalized cytokine therapy.

Main Methods:

  • Review of existing literature on cytokine pharmacogenetics.
  • Analysis of genetic factors influencing immune response to cytokine therapies.
  • Evaluation of potential clinical applications and economic impact.

Main Results:

  • Genetic profiling can identify patients most likely to benefit from cytokine therapies.
  • Personalized approaches may enhance treatment efficacy.
  • Potential for improved therapeutic outcomes and pharmacoeconomic advantages.

Conclusions:

  • Cytokine pharmacogenetics offers a promising strategy for optimizing therapy.
  • Targeting treatments based on genetic profiles can improve patient outcomes.
  • Personalized cytokine therapy may lead to significant pharmacoeconomic benefits.